MOF maintains transcriptional programs regulating cellular stress response
Standard
MOF maintains transcriptional programs regulating cellular stress response. / Sheikh, B N; Bechtel-Walz, W; Lucci, J; Karpiuk, O; Hild, I; Hartleben, B; Vornweg, J; Helmstädter, M; Sahyoun, A H; Bhardwaj, V; Stehle, T; Diehl, S; Kretz, O; Voss, A K; Thomas, T; Manke, T; Huber, T B; Akhtar, A.
In: ONCOGENE, Vol. 35, No. 21, 05.2016, p. 2698-710.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - MOF maintains transcriptional programs regulating cellular stress response
AU - Sheikh, B N
AU - Bechtel-Walz, W
AU - Lucci, J
AU - Karpiuk, O
AU - Hild, I
AU - Hartleben, B
AU - Vornweg, J
AU - Helmstädter, M
AU - Sahyoun, A H
AU - Bhardwaj, V
AU - Stehle, T
AU - Diehl, S
AU - Kretz, O
AU - Voss, A K
AU - Thomas, T
AU - Manke, T
AU - Huber, T B
AU - Akhtar, A
PY - 2016/5
Y1 - 2016/5
N2 - MOF (MYST1, KAT8) is the major H4K16 lysine acetyltransferase (KAT) in Drosophila and mammals and is essential for embryonic development. However, little is known regarding the role of MOF in specific cell lineages. Here we analyze the differential role of MOF in proliferating and terminally differentiated tissues at steady state and under stress conditions. In proliferating cells, MOF directly binds and maintains the expression of genes required for cell cycle progression. In contrast, MOF is dispensable for terminally differentiated, postmitotic glomerular podocytes under physiological conditions. However, in response to injury, MOF is absolutely critical for podocyte maintenance in vivo. Consistently, we detect defective nuclear, endoplasmic reticulum and Golgi structures, as well as presence of multivesicular bodies in vivo in podocytes lacking Mof following injury. Undertaking genome-wide expression analysis of podocytes, we uncover several MOF-regulated pathways required for stress response. We find that MOF, along with the members of the non-specific lethal but not the male-specific lethal complex, directly binds to genes encoding the lysosome, endocytosis and vacuole pathways, which are known regulators of podocyte maintenance. Thus, our work identifies MOF as a key regulator of cellular stress response in glomerular podocytes.
AB - MOF (MYST1, KAT8) is the major H4K16 lysine acetyltransferase (KAT) in Drosophila and mammals and is essential for embryonic development. However, little is known regarding the role of MOF in specific cell lineages. Here we analyze the differential role of MOF in proliferating and terminally differentiated tissues at steady state and under stress conditions. In proliferating cells, MOF directly binds and maintains the expression of genes required for cell cycle progression. In contrast, MOF is dispensable for terminally differentiated, postmitotic glomerular podocytes under physiological conditions. However, in response to injury, MOF is absolutely critical for podocyte maintenance in vivo. Consistently, we detect defective nuclear, endoplasmic reticulum and Golgi structures, as well as presence of multivesicular bodies in vivo in podocytes lacking Mof following injury. Undertaking genome-wide expression analysis of podocytes, we uncover several MOF-regulated pathways required for stress response. We find that MOF, along with the members of the non-specific lethal but not the male-specific lethal complex, directly binds to genes encoding the lysosome, endocytosis and vacuole pathways, which are known regulators of podocyte maintenance. Thus, our work identifies MOF as a key regulator of cellular stress response in glomerular podocytes.
KW - Animals
KW - Cell Cycle Checkpoints
KW - Heat-Shock Proteins
KW - Histone Acetyltransferases
KW - Humans
KW - Mice
KW - Mice, Inbred C57BL
KW - Mice, Transgenic
KW - Nuclear Proteins
KW - Podocytes
KW - Scavenger Receptors, Class A
KW - Stress, Physiological
KW - Transcription, Genetic
KW - Journal Article
U2 - 10.1038/onc.2015.335
DO - 10.1038/onc.2015.335
M3 - SCORING: Journal article
C2 - 26387537
VL - 35
SP - 2698
EP - 2710
JO - ONCOGENE
JF - ONCOGENE
SN - 0950-9232
IS - 21
ER -